ISPCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

iSpecimen Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.91−0.01 (-0.75%)

Close on Oct 19, 2026

Market cap: $1.27M
P/E (TTM): –
Dividend yield: –

iSpecimen Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	1.93	9.29	9.93	10	11	8.18
Cost of Revenue	1.71	5.11	4.77	4.76	5.25	3.59
Gross Profit	0.22	4.18	5.16	5.65	5.89	4.60
Research & Development	–	1.49	1.62	1.47	0.88	0.32
Selling, General & Admin	5.77	11	9.89	10	8.04	4.18
Selling & Marketing	2.30	4.95	3.96	3.45	2.42	1.78
General & Administrative	3.47	6.07	5.94	6.93	5.61	2.40
Advertising Expenses	–	0.36	0.22	0.19	0.23	0.11
Total Costs & Expenses	11	22	21	21	17	11
Operating Income	-8.98	-13	-11	-10	-5.93	-2.41
Interest Expense	0.00	0.17	0.02	0.24	2.10	2.10
Interest & Investment Income	0.00	0.04	0.34	0.17	0.01	0.00
Other Non-Operating Income	-1.51	0.23	0.07	-0.06	-3.04	-2.25
Asset Impairment Charges	–	–	–	–	0	0
Gain (Loss) on Sale of Assets	–	0.00	–	–	–	–
Income Tax Expense	–	–	–	0	0	0
Net Income	-10	-12	-11	-10	-8.96	-4.65
EPS (Basic)(per share)	-91.20	-703.20	-982.00	-928.00	-1,672.00	-3,976.00
EPS (Diluted)(per share)	-91.20	-703.20	-982.00	-928.00	-1,672.00	-3,976.00
Shares Outstanding (Basic, Weighted)(shares)	0.12	0.02	0.01	0.01	0.01	0.00
Shares Outstanding (Diluted, Weighted)(shares)	0.12	0.02	0.01	0.01	0.01	0.00
EBITDA	-7.25	-10	-9.05	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -98.0%
Operating margin: -2020.0%
Net margin: -2449.0%
Return on equity, FY2025: -327.8%

Financial strength

Current ratio: 0.82
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 80.6%

Valuation

P/E ratio: –
Price to sales: 2.72
Price to book: 0.73
Dividend yield: –